Stemirac - Japanese Stem Cell Therapy for Spinal Cord Injuries
For many years, a spinal cord injury meant permanent loss of function below the level of injury for most patients. Modern medicine is becoming increasingly effective at saving the lives of people who have suffered serious accidents, stabilising the spine and providing rehabilitation. However, restoring damaged neural connections remains one of the greatest challenges in neurology. Scientists have long been searching for methods that could not only reduce the consequences of an injury but also support the regeneration of the nervous system. One of the areas of research involves the use of stem cells.
A particularly interesting example of the application of this technology is the Japanese product Stemirac, developed by NIPRO in cooperation with Sapporo Medical University. The product is made from stem cells collected from the patient's own bone marrow and is intended to treat the consequences of traumatic spinal cord injuries. In November 2026, very important news emerged. Japan's Ministry of Health granted Stemirac full marketing approval following an earlier period of conditional approval. This represents a significant step forward in regenerative medicine and is important news for people living with spinal cord injuries.
What is Stemirac?
Stemirac (STEMIRAC Injection) is a regenerative medicine product containing human autologous mesenchymal stem cells derived from bone marrow. It is worth explaining two important terms.
Autologous means that the cells used in the treatment come from the patient themselves. They are not collected from a donor or another person.
Mesenchymal stem cells (MSCs) are cells found, among other places, in bone marrow. They have the ability to differentiate into certain types of cells and to secrete various biologically active substances that may influence the functioning of other cells and the body's repair processes.
The product was developed in Japan on the basis of many years of research conducted by Professor Osamu Honmou's team at Sapporo Medical University. NIPRO participated in the work to bring the treatment into clinical use, taking responsibility for developing the manufacturing technology and commercialising the product. Stemirac is not a conventional pharmaceutical drug. It is a specially prepared cell-based product whose main component consists of the patient's own living cells.
How is Stemirac produced?
One of the most important features of this therapy is the use of the patient's own cells. The process begins with the collection of biological material, which is then sent to a specialised laboratory. The procedure involves several stages.
1. Bone marrow collection
Bone marrow is collected from the patient, usually from the pelvic bone area. A sample of peripheral blood is also taken to obtain material used in preparing the product.
2. Isolation of stem cells
In the laboratory, mesenchymal stem cells are isolated from the collected bone marrow. They are then subjected to appropriate cell culture procedures.
3. Cell expansion
The isolated cells are placed in controlled laboratory conditions, where they can multiply. The aim is to obtain the required number of cells needed to prepare a therapeutic dose.
4. Preparation of the product
Once the cell culture process is complete, the cells are appropriately prepared and stored under conditions that allow them to be used later.
5. Administration to the patient
The finished product is administered intravenously as an infusion. The procedure does not therefore involve directly implanting cells into the site of the spinal cord injury. According to the 2018 regulatory documentation, the dose ranged from 50 to 200 million cells. The detailed preparation and administration of the product are carried out as part of a specialised medical procedure.
How can stem cells help an injured spinal cord?
This is the most important aspect of the entire technology. A severe spinal cord injury causes not only direct damage to nerve cells and their extensions, but also triggers secondary processes that damage the tissue. These include inflammation, impaired blood supply, swelling and reactions that lead to further cell death. Even if some nerve fibres were not directly destroyed at the time of the accident, they may become damaged as a result of these processes. The mesenchymal cells used in Stemirac have several properties that may be beneficial in such circumstances.
Neuroprotective effects
The cells may secrete substances known as neurotrophic factors. These compounds support the survival and functioning of nerve cells. They may also help limit processes that cause further damage to them.
Effects on inflammation
Mesenchymal stem cells have immunomodulatory properties. This means that they may influence the activity of the immune system and reduce harmful inflammatory responses in damaged tissue.
Influence on regenerative processes
The cells may interact with the environment of the injured spinal cord, supporting repair processes and the activity of other cells.
Potential differentiation into cells of the nervous system
Research into mesenchymal cells also examines their ability to differentiate into cells with characteristics of nerve cells. However, this does not mean that, after Stemirac is administered, the cells automatically replace destroyed neurons and restore interrupted neural connections. It is important to understand that the product does not rely on a single mechanism of action. Its potential beneficial effects are thought to result from several biological processes working together. Scientists are not claiming that administering stem cells guarantees the reconstruction of a severed spinal cord. The aim is to improve nervous system function and reduce the consequences of the injury.
First clinical trials - where did the hopes come from?
The development of Stemirac took many years. Following laboratory research and preclinical experiments, clinical trials involving patients with traumatic spinal cord injuries were initiated. The results of a small clinical trial were particularly important. They formed the basis for the product's initial approval for use in Japan.
Among other things, the study assessed changes in the AIS (ASIA Impairment Scale), which is used to determine the severity of spinal cord injuries. The scale comprises five categories:
- AIS A - complete spinal cord injury according to the criteria of the neurological examination.
- AIS B - sensory function is preserved below the level of injury, but motor function does not meet the criteria for this category.
- AIS C - motor function is preserved, but most of the key muscles below the neurological level of injury do not have sufficient strength to produce functional movement against gravity.
- AIS D - motor function is preserved, and at least half of the key muscles below the level of injury have a strength grade of at least 3 on the Lovett scale.
- AIS E - normal sensory and motor function on neurological examination.
The Stemirac study included 13 patients with traumatic spinal cord injuries classified as AIS A, B or C. Following administration of the product, 12 out of 13 patients showed an improvement of at least one grade on the AIS scale. The results were as follows:
- AIS A - improvement was observed in 5 out of 6 patients.
- AIS B - improvement was observed in 2 out of 2 patients.
- AIS C - improvement was observed in 5 out of 5 patients.
Overall, this represented an improvement in 92.3 per cent of the study participants. These results attracted the attention of the medical community and became one of the arguments in favour of further developing this treatment method.
However, it is important to remember a significant limitation: the study included only 13 people. It was not a large randomised controlled trial that would make it possible to clearly distinguish the effects of the therapy from the natural recovery of neurological function. Particularly during the first months after an injury, some patients may experience spontaneous improvement. Therefore, the fact that improvement occurs after the product is administered does not in itself prove that it was caused solely by stem cells. This is precisely why a much larger body of data on the effectiveness and safety of the therapy was needed.
2018 - First Approval for Use in Japan
On 28 December 2018, Japan's Ministry of Health granted Stemirac conditional and time-limited marketing approval. This was an important moment in the history of regenerative medicine. Stemirac became the first product of its kind to be approved in Japan for the treatment of the consequences of traumatic spinal cord injuries.
The use of a special regulatory approval procedure was related to the nature of regenerative medicine. In the case of innovative cell therapies, obtaining a large amount of clinical data before approval can be particularly challenging. The Japanese system provided for the possibility of conditional approval if the available data indicated a certain level of efficacy and an acceptable safety profile, while requiring further assessment of the therapy after it had been introduced.
However, this did not mean that the product had been recognised as a treatment with definitively proven efficacy. Under the conditions of the initial approval, the therapy was intended for patients with traumatic spinal cord injuries classified as AIS A, B or C. Another important requirement was that bone marrow had to be collected sufficiently early after the injury.
The documentation stipulated that bone marrow collection should, in principle, take place within 31 days of the injury, depending on the patient's overall condition. Once prepared, the product was to be administered as soon as possible. Treatment could only be carried out at appropriately equipped medical centres under the supervision of doctors experienced in treating spinal cord injuries.
Seven Years of Monitoring - The Road to Full Approval
The conditional approval granted in 2018 marked the beginning of another stage. The manufacturer was required to collect data on patients receiving the therapy under real-world clinical conditions. The observations covered both the effectiveness and safety of the product.
The focus was no longer exclusively on the results of a small clinical trial. It became important to determine how the therapy performed in everyday medical practice, in patients with varying degrees of spinal cord injury and different consequences of trauma. In November 2025, NIPRO submitted an application for full marketing approval. Following an assessment of the collected data, Japan's Ministry of Health made the decision that had been awaited for years.
16 November 2026 - Stemirac Receives Full Marketing Approval!
This is the most important recent development concerning this therapy. On 16 November 2026, NIPRO announced that Japan's Ministry of Health had granted Stemirac full marketing approval.
This is the first case in Japan in which a regenerative medicine product has received full approval after previously being granted conditional and time-limited approval under the special procedure designed for this type of therapy. The announcement was also confirmed by Sapporo Medical University, which had been involved in the development of the product from the beginning.
What does this mean in practice? First and foremost, it means that Stemirac has passed another stage of regulatory assessment. The data collected on the use of the product made it possible to obtain full approval, and the therapy can continue to be offered to patients in Japan. It is no longer solely an experimental method available as part of clinical trials. The product now has the status of an approved regenerative medicine product.
It is important to emphasise, however, that full approval does not guarantee that every patient will regain their physical abilities. Nor does it mean that the therapy can completely reconstruct a destroyed spinal cord. This is an important advance, but not a miracle cure for paralysis.
Can Stemirac Help People with Tetraplegia and Paraplegia?
Tetraplegia and paraplegia are consequences of spinal cord injuries that can lead to permanent loss of motor and sensory function. Injuries to the cervical spinal cord can result in paralysis of all four limbs, while injuries to the thoracic and lumbar regions may cause paraplegia.
Stemirac was developed to treat the neurological consequences of traumatic spinal cord injuries, which means that its potential applications also include patients with tetraplegia and paraplegia. However, it is very important to distinguish between the possibility of using a therapy and its proven effectiveness in a specific group of patients.
The original indications covered people with traumatic spinal cord injuries classified as AIS A, B or C. The therapy was intended for use during the early period following an injury, rather than for people who have been living with permanent paralysis for many years. This is a fundamental difference.
What About People Who Sustained a Spinal Cord Injury Many Years Ago?
This is precisely where the greatest number of questions and hopes arise. In people with long-standing spinal cord injuries, the biological situation is different from that immediately after an accident. The processes associated with acute inflammation and secondary tissue damage ended long ago, and a glial scar and permanent structural changes may have developed at the site of the injury. It is therefore impossible to automatically assume that a method effective during the first weeks after an injury will be equally effective after five, ten or thirty years.
It is worth noting, however, that Japanese researchers and NIPRO have not limited their interest exclusively to recent injuries. A Phase II clinical trial involving patients with chronic spinal cord injuries has also been registered in Japan. The study was designed for people classified as AIS C and D, with the aim of assessing the safety and effectiveness of intravenous administration of autologous mesenchymal cells.
This is a particularly interesting area of research because it concerns patients who are beyond the acute phase following their injury. However, it must be clearly emphasised that conducting such a study does not prove that the therapy works in people with long-standing, complete tetraplegia or paraplegia. Nor does it mean that the treatment has already been approved for all patients with chronic spinal cord injuries.
The study involving chronic injuries is a separate stage of scientific research and should not be confused with the product's current approved indications. For people who have been living with a spinal cord injury for many years, the results of these studies will be particularly important.
Does Stemirac Mean That Patients May Regain the Ability to Walk?
It is important to be particularly cautious about such expectations. An improvement in the AIS grade is not equivalent to regaining the ability to walk. The scale assesses sensory and motor function, and a change in category can represent different degrees of improvement in individual patients.
One person may experience an improvement in muscle strength, another may regain some sensation, while for someone else the change may have an impact on everyday functioning. It is therefore impossible to promise that a patient with tetraplegia will regain arm function, start walking independently or no longer need a wheelchair.
Nevertheless, even a small improvement in neurological function can be extremely significant for many people. It may mean greater independence, easier rehabilitation or an improved ability to perform everyday activities. This is precisely why further research into regenerative therapies is so important.
Therapy Safety - Are Stem Cells Completely Safe?
The use of the patient's own cells has an important advantage: it reduces certain problems associated with the use of biological material obtained from another person. However, this does not mean that the procedure is entirely risk-free.
Bone marrow collection is a medical procedure that may involve pain, bleeding or other complications. Blood collection and intravenous administration of the product also require appropriate medical supervision. The documentation from the initial clinical trial reported, among other things, cases of anaemia associated with blood collection and pain at the puncture site during bone marrow harvesting.
Monitoring patients after administration of the product and conducting further follow-up assessments are also important. Full product approval means that the Japanese regulatory authorities considered the available data sufficient to conclude the conditional approval procedure. However, it does not mean that all possible adverse effects have been ruled out. As with any new medical technology, continued collection of clinical experience remains necessary.
Will Stemirac Be Available in Poland?
As of 20 November 2026, full approval for Stemirac applies to Japan. Japanese marketing authorisation should not be confused with automatic approval of the product in the European Union.
For the therapy to be routinely offered to patients in Poland, the relevant regulatory and organisational requirements would have to be met. The availability of specialised centres, the ability to prepare the product and the funding of treatment are also important factors. Sapporo Medical University announced that, following full approval, Stemirac would continue to be offered in Japan at centres equipped to provide this type of treatment.
However, this does not mean that a patient from Poland can simply visit any Japanese hospital and receive the therapy. Eligibility depends on medical indications, the patient's condition and the applicable treatment requirements. Anyone interested in this method should primarily rely on information provided by the manufacturer, medical centres and the relevant regulatory authorities.
Hope for the Future, but Without False Promises
The development of Stemirac is an important event for regenerative medicine. For the first time, a product intended to treat the consequences of traumatic spinal cord injuries has completed the entire approval process in Japan, progressing from conditional approval to full marketing authorisation. This is an important indication that research into the use of stem cells is no longer limited exclusively to laboratories and experimental studies. At the same time, we must not forget that the road towards effective treatment of chronic spinal cord injuries remains long.
For people who sustained an injury many years ago, the results of studies investigating the use of this therapy in the chronic phase of spinal cord injury will be particularly important. These studies may help answer the question of whether stem cells can also benefit patients who sustained their injuries many years ago.
It is worth following the development of this technology, but it should not be regarded as a guarantee of regaining physical function, nor should anyone abandon existing rehabilitation methods or medical care. Every further step towards a better understanding of spinal cord regeneration is important. Perhaps the future will bring methods that make it possible to provide more effective help to people who have been living with tetraplegia and paraplegia for many years.
Sources and Further Reading
- NIPRO - official announcement of full Stemirac approval, 16 November 2026.
- Sapporo Medical University - announcement concerning full product approval, 17 November 2026.
- PMDA - Stemirac assessment report, 2018.
- Japanese Clinical Trials Registry - Stemirac study involving chronic spinal cord injuries.
PL
DE